Disease-modifying antirheumatic drug selection in Japanese patients with rheumatoid arthritis treated with biologics or JAK inhibitors without methotrexate: A retrospective hospital-based administrative claims database study.
Naohisa MiyakawaKatsuki TsuritaniBruno Casaes TeixeiraKeishi FujioPublished in: Modern rheumatology (2024)
MTX is used less frequently among older Japanese rheumatoid arthritis patients or those with comorbidities. In such patients, ABA is the most frequently used drug, followed by interleukin-6 receptor inhibitor, when MTX is not used at treatment start.
Keyphrases
- rheumatoid arthritis patients
- end stage renal disease
- newly diagnosed
- disease activity
- ejection fraction
- chronic kidney disease
- rheumatoid arthritis
- peritoneal dialysis
- prognostic factors
- systemic lupus erythematosus
- emergency department
- patient reported outcomes
- low dose
- arabidopsis thaliana
- smoking cessation
- electronic health record